said the completion date for its planned merger to form GlaxoSmithKline will be delayed until after the previously announced date of September 25.
It is now expected the merger will be completed by the end of this year.
Federal Trade Commission
recently requested additional information about the smoking cessation product area. Glaxo Wellcome markets the prescription product Zyban, and SmithKline Beecham's consumer healthcare business markets the over-the-counter products Nicorette and Nicoderm. The companies have already divested product lines to help them clear anti-trust hurdles.
The European Commission gave regulatory approval for the merger in May.